# Myomo, Inc.: overview MYO · NYSE · CIK 1369290 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/myo.md) · [Financials](/companies/myo/financials.md) · [Filings](/companies/myo/filings.md) · [Insiders](/companies/myo/insiders.md) Latest reported revenue: [$11.7m](/filings/0001193125-26-335149.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335149). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.2](/filings/0001193125-25-274278.md) | [12.1 d](/filings/0001193125-26-098531.md) | [9.8](/filings/0001193125-26-211988.md) | [9.7](/filings/0001193125-26-335149.md) | [10.1](/filings/0001193125-25-274278.md) | [11.4 d](/filings/0001193125-26-098531.md) | [10.1](/filings/0001193125-26-211988.md) | [11.7](/filings/0001193125-26-335149.md) | | Gross margin | % | [75.4%](/filings/0001193125-25-274278.md) | [71.4% d](/filings/0001193125-26-098531.md) | [67.2%](/filings/0001193125-26-211988.md) | [62.7%](/filings/0001193125-26-335149.md) | [63.8%](/filings/0001193125-25-274278.md) | [68.6% d](/filings/0001193125-26-098531.md) | [68.2%](/filings/0001193125-26-211988.md) | [72.1%](/filings/0001193125-26-335149.md) | | Operating margin | % | [(10.4%)](/filings/0001193125-25-274278.md) | [(2.0%) d](/filings/0001193125-26-098531.md) | [(35.8%)](/filings/0001193125-26-211988.md) | [(47.6%)](/filings/0001193125-26-335149.md) | [(34.9%)](/filings/0001193125-25-274278.md) | [(24.4%) d](/filings/0001193125-26-098531.md) | [(31.2%)](/filings/0001193125-26-211988.md) | [(19.3%)](/filings/0001193125-26-335149.md) | | Net margin | % | [(10.5%)](/filings/0001193125-25-274278.md) | [(2.2%) d](/filings/0001193125-26-098531.md) | [(35.2%)](/filings/0001193125-26-335149.md) | [(48.0%)](/filings/0001193125-26-335149.md) | [(36.3%)](/filings/0001193125-25-274278.md) | [(33.6%) d](/filings/0001193125-26-098531.md) | [(29.8%)](/filings/0001193125-26-335149.md) | [(34.4%)](/filings/0001193125-26-335149.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001193125-25-274278.md) | not reported | [(0.08)](/filings/0001193125-26-211988.md) | [(0.11)](/filings/0001193125-26-335149.md) | [(0.09)](/filings/0001193125-25-274278.md) | not reported | [(0.07)](/filings/0001193125-26-211988.md) | [(0.09)](/filings/0001193125-26-335149.md) | | Free cash flow | $m | [(1.8) d](/filings/0001193125-25-274278.md) | [2.5 d](/filings/0001193125-26-098531.md) | [(3.3)](/filings/0001193125-26-211988.md) | [(9.1) d](/filings/0001193125-26-335149.md) | [(3.9) d](/filings/0001193125-25-274278.md) | [(2.4) d](/filings/0001193125-26-098531.md) | [(2.5)](/filings/0001193125-26-211988.md) | [(2.0) d](/filings/0001193125-26-335149.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.9](/filings/0000950170-23-007560.md) | [15.6](/filings/0000950170-24-028326.md) | [19.2](/filings/0000950170-25-036349.md) | [32.6](/filings/0001193125-26-098531.md) | [40.9](/filings/0001193125-26-098531.md) | | Gross margin | % | [74.4%](/filings/0000950170-23-007560.md) | [65.9%](/filings/0000950170-24-028326.md) | [68.5%](/filings/0000950170-25-036349.md) | [71.2%](/filings/0001193125-26-098531.md) | [65.7%](/filings/0001193125-26-098531.md) | | Operating margin | % | [(74.1%)](/filings/0000950170-23-007560.md) | [(68.6%)](/filings/0000950170-24-028326.md) | [(42.8%)](/filings/0000950170-25-036349.md) | [(19.1%)](/filings/0001193125-26-098531.md) | [(35.2%)](/filings/0001193125-26-098531.md) | | Net margin | % | [(74.9%)](/filings/0000950170-23-007560.md) | [(68.9%)](/filings/0000950170-24-028326.md) | [(42.3%)](/filings/0000950170-25-036349.md) | [(19.0%)](/filings/0001193125-26-098531.md) | [(38.1%)](/filings/0001193125-26-098531.md) | | Diluted EPS | $ per share | [(1.89)](/filings/0000950170-23-007560.md) | [(1.52)](/filings/0000950170-24-028326.md) | [(0.28)](/filings/0000950170-25-036349.md) | [(0.16)](/filings/0001193125-26-098531.md) | [(0.37)](/filings/0001193125-26-098531.md) | | Free cash flow | $m | [(9.9)](/filings/0000950170-23-007560.md) | [(10.3)](/filings/0000950170-24-028326.md) | [(6.3)](/filings/0000950170-25-036349.md) | [(4.7)](/filings/0001193125-26-098531.md) | [(16.3)](/filings/0001193125-26-098531.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/myo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $3.8m | 3,637,886 | | Reduced −209,386 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 1,636,570 | | Added +492,246 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $965.4k | 928,268 | | Added +609,317 | | [Jefferies Financial Group Inc.](/funds/96223.md) | 2026-06-30 | $732.4k | 704,275 | | Unchanged | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $620.2k | 596,352 | | New +596,352 | | [Clearstead Advisors, LLC](/funds/842775.md) | 2026-06-30 | $442.6k | 425,609 | | Added +9 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $430.2k | 413,679 | | Added +101,958 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $358.3k | 344,417 | | Reduced −514,382 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $320.3k | 308,000 | | Added +2,000 | | [Palumbo Wealth Management LLC](/funds/1846310.md) | 2026-06-30 | $311.8k | 299,776 | | New +299,776 | ## Recent filings [All 688 filings](/companies/myo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 20:15 ET | [10-Q](/filings/0001193125-26-335149.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335149 | | 2026-08-05 | 20:10 ET | [8-K](/filings/0001193125-26-335109.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335109 | | 2026-06-29 | 13:06 ET | [8-K/A](/filings/0001193125-26-286969.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-286969 | | 2026-06-26 | 20:05 ET | [8-K](/filings/0001193125-26-285450.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-285450 | | 2026-05-18 | 22:05 ET | [SCHEDULE 13D/A](/filings/0001161697-26-000118.md) | Ownership report, active investor, amended | 0001161697-26-000118 | | 2026-05-14 | 20:05 ET | [DEF 14A](/filings/0001193125-26-223981.md) | Proxy statement, period 2026-06-25 | 0001193125-26-223981 | | 2026-05-13 | 20:10 ET | [8-K](/filings/0001193125-26-221624.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-221624 | | 2026-05-07 | 20:17 ET | [10-Q](/filings/0001193125-26-211988.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211988 | | 2026-05-07 | 20:12 ET | [8-K](/filings/0001193125-26-211928.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211928 | | 2026-04-29 | 20:05 ET | [10-K/A](/filings/0001193125-26-191496.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-191496 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-098531.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d63281df-2eaf-4041-8000-98eebf47e3c2) ## About the filer - CIK: 1369290 - Tickers: MYO - Exchange: NYSE - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.